WESTMINSTER, Colo., Nov. 18, 2016 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced it has received a Best New Technology Award for spine care as part of the 2016 Orthopedics This Week Spine Technology Awards. The award recognizes the company’s i-FACTOR™ Peptide Enhanced Bone Graft, the first bone graft to be approved for use in the cervical spine by the U.S. Food and Drug Administration (FDA WESTMINSTER). Award winners were announced in conjunction with the 2016 North American Spine Society (NASS) Annual Meeting, held October 26-29 in Boston, MA.
“Over the past year we have been focused on accelerating our commercialization efforts in the U.S. following the FDA Premarket Approval (PMA) of i-FACTOR Bone Graft,” said Glen Kashuba, CEO of Cerapedics. “We continue to receive outstanding feedback from surgeons across the country who are excited to have a safe, clinically effective and cost effective bone graft that is supported by Level I human data. We are grateful to be recognized by Orthopedics This Week and the surgeon panel who chose i-FACTOR Bone Graft for the Best New Technology Award.”
i‐FACTOR Bone Graft is based on synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attachment and activation. In November 2015, i-FACTOR Bone Graft was approved by the FDA for use in anterior cervical discectomy and fusion (ACDF) procedures in patients with degenerative cervical disc disease.
The annual Orthopedics This Week Spine Technology Awards honor inventors, engineering teams, surgeons and their companies who have created the most innovative, enduring and practical products to treat back pain. For more information, visit https://ryortho.com/2016/11/the-ten-best-new-spine-technologies-for-2016/.
Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform. i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at www.cerapedics.com.
Berry & Company Public Relations